Free Trial

NIOX Group (NIOX) Competitors

NIOX Group logo
GBX 62 -2.80 (-4.32%)
As of 11:57 AM Eastern

NIOX vs. AMS, TSTL, EKF, SPEC, and CREO

Should you buy NIOX Group stock or one of its competitors? NIOX Group's main competitors and comparable companies include Advanced Medical Solutions Group (AMS), Tristel (TSTL), EKF Diagnostics (EKF), INSPECS Group (SPEC), and Creo Medical Group (CREO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does NIOX Group compare to Advanced Medical Solutions Group?

Advanced Medical Solutions Group (LON:AMS) and NIOX Group (LON:NIOX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Advanced Medical Solutions Group has a beta of 0.759, indicating that its share price is 24% less volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

Advanced Medical Solutions Group pays an annual dividend of GBX 2.86 per share and has a dividend yield of 1.0%. NIOX Group pays an annual dividend of GBX 1.55 per share and has a dividend yield of 2.4%. Advanced Medical Solutions Group pays out 173.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. NIOX Group pays out 95.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. NIOX Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

Advanced Medical Solutions Group presently has a consensus target price of GBX 278.33, indicating a potential downside of 1.65%. NIOX Group has a consensus target price of GBX 86, indicating a potential upside of 35.29%. Given NIOX Group's stronger consensus rating and higher possible upside, analysts plainly believe NIOX Group is more favorable than Advanced Medical Solutions Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Advanced Medical Solutions Group
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

NIOX Group has lower revenue, but higher earnings than Advanced Medical Solutions Group. NIOX Group is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanced Medical Solutions Group£233.63M2.64£11.22M£1.65171.52
NIOX Group£47.50M5.42£995.88M£1.6339.00

NIOX Group has a net margin of 14.74% compared to Advanced Medical Solutions Group's net margin of 1.58%. NIOX Group's return on equity of 10.01% beat Advanced Medical Solutions Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Advanced Medical Solutions Group1.58% 1.44% 2.35%
NIOX Group 14.74%10.01%3.95%

In the previous week, NIOX Group had 1 more articles in the media than Advanced Medical Solutions Group. MarketBeat recorded 1 mentions for NIOX Group and 0 mentions for Advanced Medical Solutions Group. Advanced Medical Solutions Group's average media sentiment score of 0.80 beat NIOX Group's score of 0.76 indicating that Advanced Medical Solutions Group is being referred to more favorably in the media.

Company Overall Sentiment
Advanced Medical Solutions Group Positive
NIOX Group Positive

21.5% of Advanced Medical Solutions Group shares are owned by institutional investors. Comparatively, 7.6% of NIOX Group shares are owned by institutional investors. 4.0% of Advanced Medical Solutions Group shares are owned by insiders. Comparatively, 5.1% of NIOX Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

NIOX Group beats Advanced Medical Solutions Group on 12 of the 17 factors compared between the two stocks.

How does NIOX Group compare to Tristel?

NIOX Group (LON:NIOX) and Tristel (LON:TSTL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

NIOX Group currently has a consensus target price of GBX 86, suggesting a potential upside of 35.29%. Given NIOX Group's stronger consensus rating and higher probable upside, analysts plainly believe NIOX Group is more favorable than Tristel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Tristel
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

NIOX Group has higher earnings, but lower revenue than Tristel. Tristel is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NIOX Group£47.50M5.42£995.88M£1.6339.00
Tristel£51.12M3.67£6.54M£16.5723.57

7.6% of NIOX Group shares are owned by institutional investors. Comparatively, 22.4% of Tristel shares are owned by institutional investors. 5.1% of NIOX Group shares are owned by company insiders. Comparatively, 21.0% of Tristel shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

NIOX Group pays an annual dividend of GBX 1.55 per share and has a dividend yield of 2.4%. Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.6%. NIOX Group pays out 95.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel pays out 85.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel is clearly the better dividend stock, given its higher yield and lower payout ratio.

Tristel has a net margin of 15.62% compared to NIOX Group's net margin of 14.74%. Tristel's return on equity of 23.05% beat NIOX Group's return on equity.

Company Net Margins Return on Equity Return on Assets
NIOX Group14.74% 10.01% 3.95%
Tristel 15.62%23.05%9.89%

In the previous week, NIOX Group had 1 more articles in the media than Tristel. MarketBeat recorded 1 mentions for NIOX Group and 0 mentions for Tristel. NIOX Group's average media sentiment score of 0.76 beat Tristel's score of 0.00 indicating that NIOX Group is being referred to more favorably in the media.

Company Overall Sentiment
NIOX Group Positive
Tristel Neutral

NIOX Group has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market. Comparatively, Tristel has a beta of 0.352, meaning that its share price is 65% less volatile than the broader market.

Summary

NIOX Group and Tristel tied by winning 9 of the 18 factors compared between the two stocks.

How does NIOX Group compare to EKF Diagnostics?

NIOX Group (LON:NIOX) and EKF Diagnostics (LON:EKF) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

NIOX Group has higher earnings, but lower revenue than EKF Diagnostics. NIOX Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NIOX Group£47.50M5.42£995.88M£1.6339.00
EKF Diagnostics£51.35M2.03£4.68M£0.5841.90

7.6% of NIOX Group shares are held by institutional investors. Comparatively, 21.5% of EKF Diagnostics shares are held by institutional investors. 5.1% of NIOX Group shares are held by company insiders. Comparatively, 40.2% of EKF Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

NIOX Group has a net margin of 14.74% compared to EKF Diagnostics' net margin of 4.86%. NIOX Group's return on equity of 10.01% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
NIOX Group14.74% 10.01% 3.95%
EKF Diagnostics 4.86%3.58%5.27%

In the previous week, NIOX Group had 1 more articles in the media than EKF Diagnostics. MarketBeat recorded 1 mentions for NIOX Group and 0 mentions for EKF Diagnostics. NIOX Group's average media sentiment score of 0.76 beat EKF Diagnostics' score of 0.00 indicating that NIOX Group is being referred to more favorably in the media.

Company Overall Sentiment
NIOX Group Positive
EKF Diagnostics Neutral

NIOX Group currently has a consensus target price of GBX 86, suggesting a potential upside of 35.29%. EKF Diagnostics has a consensus target price of GBX 35, suggesting a potential upside of 44.03%. Given EKF Diagnostics' higher probable upside, analysts plainly believe EKF Diagnostics is more favorable than NIOX Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

NIOX Group has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.503, suggesting that its share price is 50% less volatile than the broader market.

Summary

NIOX Group beats EKF Diagnostics on 8 of the 14 factors compared between the two stocks.

How does NIOX Group compare to INSPECS Group?

NIOX Group (LON:NIOX) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

NIOX Group has a net margin of 14.74% compared to INSPECS Group's net margin of -0.52%. NIOX Group's return on equity of 10.01% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
NIOX Group14.74% 10.01% 3.95%
INSPECS Group -0.52%-1.19%0.45%

In the previous week, NIOX Group had 1 more articles in the media than INSPECS Group. MarketBeat recorded 1 mentions for NIOX Group and 0 mentions for INSPECS Group. NIOX Group's average media sentiment score of 0.76 beat INSPECS Group's score of 0.00 indicating that NIOX Group is being referred to more favorably in the media.

Company Overall Sentiment
NIOX Group Positive
INSPECS Group Neutral

NIOX Group has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NIOX Group£47.50M5.42£995.88M£1.6339.00
INSPECS Group£193.23M0.49-£4.11M-£5.34N/A

7.6% of NIOX Group shares are held by institutional investors. Comparatively, 0.7% of INSPECS Group shares are held by institutional investors. 5.1% of NIOX Group shares are held by insiders. Comparatively, 19.6% of INSPECS Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

NIOX Group presently has a consensus price target of GBX 86, suggesting a potential upside of 35.29%. Given NIOX Group's stronger consensus rating and higher possible upside, analysts clearly believe NIOX Group is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

NIOX Group has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.603, suggesting that its stock price is 60% more volatile than the broader market.

Summary

NIOX Group beats INSPECS Group on 13 of the 16 factors compared between the two stocks.

How does NIOX Group compare to Creo Medical Group?

Creo Medical Group (LON:CREO) and NIOX Group (LON:NIOX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Creo Medical Group presently has a consensus target price of GBX 40, suggesting a potential upside of 295.06%. NIOX Group has a consensus target price of GBX 86, suggesting a potential upside of 35.29%. Given Creo Medical Group's higher possible upside, equities research analysts clearly believe Creo Medical Group is more favorable than NIOX Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Creo Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

44.0% of Creo Medical Group shares are owned by institutional investors. Comparatively, 7.6% of NIOX Group shares are owned by institutional investors. 7.6% of Creo Medical Group shares are owned by insiders. Comparatively, 5.1% of NIOX Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Creo Medical Group and Creo Medical Group both had 1 articles in the media. NIOX Group's average media sentiment score of 0.76 beat Creo Medical Group's score of 0.00 indicating that NIOX Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Creo Medical Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
NIOX Group
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Creo Medical Group has a beta of 1.563854, suggesting that its stock price is 56% more volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

NIOX Group has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£7M6.50-£25.04M-£5.00N/A
NIOX Group£47.50M5.42£995.88M£1.6339.00

NIOX Group has a net margin of 14.74% compared to Creo Medical Group's net margin of -268.57%. NIOX Group's return on equity of 10.01% beat Creo Medical Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group-268.57% -38.29% -20.09%
NIOX Group 14.74%10.01%3.95%

Summary

NIOX Group beats Creo Medical Group on 10 of the 15 factors compared between the two stocks.

Get NIOX Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for NIOX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NIOX vs. The Competition

MetricNIOX GroupHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£251.25M£5.99B£7.86B£2.84B
Dividend Yield2.44%1.69%2.47%5.11%
P/E Ratio38.0439.1434.4123.37
Price / Sales5.294.908.095.05
Price / Cash11.2124.1821.0220.23
Price / Book3.444.964.782.51
Net Income£995.88M£143.12M£3.52B£5.88B
7 Day Performance-3.73%-4.60%-4.98%-0.01%
1 Month Performance-8.82%-2.38%-3.20%-2.14%
1 Year Performance-10.66%-0.13%-0.27%7.21%

NIOX Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NIOX
NIOX Group
2.2517 of 5 stars
GBX 62
-4.3%
GBX 86
+38.7%
-6.6%£251.25M£47.50M38.0492
AMS
Advanced Medical Solutions Group
0.2996 of 5 stars
GBX 283
flat
GBX 278.33
-1.6%
+33.4%£616.50M£233.63M171.5210
TSTL
Tristel
N/AGBX 390.84
+0.2%
N/A+3.9%£189.89M£51.12M23.59208
EKF
EKF Diagnostics
N/AGBX 24.40
-3.6%
GBX 35
+43.4%
-7.0%£101M£51.35M42.07356
SPEC
INSPECS Group
N/AGBX 87
-3.3%
N/A+19.9%£96.62M£193.23MN/A1,673

Related Companies and Tools


This page (LON:NIOX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners